Synta's elesclomol fails Phase III melanoma trial
This article was originally published in Scrip
Executive Summary
Synta Pharmaceuticals has suspended the closely watched Phase III melanoma trial of its promising novel drug elesclomol (STA-4783) – its lead candidate which it was developing with GlaxoSmithKline – after an independent data monitoring committee (DMC) identified serious safety concerns, including more deaths in the experimental arm compared with the control chemotherapy arm.